Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Shien Lee
Kevin Sullivan

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 6, 2023
Alectinib-induced hemolytic anemiaChung-Shien Lee, Kevin Sullivan
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|December 4, 2018
Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case reportKevin Sullivan, Chung-Shien Lee
Journal of Pharmacy Practice|June 7, 2019
Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung CancerEmily Miao, Nagashree Seetharamu, Kevin Sullivan, et al.
Lung Cancer (Auckland, N.Z.)|October 29, 2020
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their ToxicityChung-Shien Lee, Sandhya Sharma, Emily Miao, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 5, 2018
Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastasesChristan M Thomas, Chung-Shien Lee
Oncotargets and Therapy|September 2, 2021
Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical DataChung-Shien Lee, Matthew Milone, Nagashree Seetharamu
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 30, 2020
Lorlatinib induced proteinuria: A case reportChung-Shien Lee, Rimda Wanchoo, Nagashree Seetharamu
Journal of Thoracic Disease|July 11, 2022
The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challengesEziafa I Oduah, Chung-Shien Lee, Nagarashee Seetharamu
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 30, 2021
A contemporary review of rearranged during transfection-selective inhibitorsAngel W Liu, Connie Liang, Chung-Shien Lee
BMJ Case Reports|August 20, 2021
Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinomaChung-Shien Lee, Emily Miao, Kasturi Das, et al.
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 6, 2023
Alectinib-induced hemolytic anemiaChung-Shien Lee, Kevin Sullivan
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|December 4, 2018
Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case reportKevin Sullivan, Chung-Shien Lee
Journal of Pharmacy Practice|June 7, 2019
Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung CancerEmily Miao, Nagashree Seetharamu, Kevin Sullivan, et al.
Lung Cancer (Auckland, N.Z.)|October 29, 2020
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their ToxicityChung-Shien Lee, Sandhya Sharma, Emily Miao, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 5, 2018
Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastasesChristan M Thomas, Chung-Shien Lee
Oncotargets and Therapy|September 2, 2021
Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical DataChung-Shien Lee, Matthew Milone, Nagashree Seetharamu
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 30, 2020
Lorlatinib induced proteinuria: A case reportChung-Shien Lee, Rimda Wanchoo, Nagashree Seetharamu
Journal of Thoracic Disease|July 11, 2022
The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma-successes and challengesEziafa I Oduah, Chung-Shien Lee, Nagarashee Seetharamu
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 30, 2021
A contemporary review of rearranged during transfection-selective inhibitorsAngel W Liu, Connie Liang, Chung-Shien Lee
BMJ Case Reports|August 20, 2021
Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinomaChung-Shien Lee, Emily Miao, Kasturi Das, et al.
Pageof 11